Neeraj Agarwal, MD, FASCO @neerajaiims Twitter profile

Pinned Tweet

Neeraj Agarwal, MD, FASCO

8 months

Just in @NatureMedicine 👉Results from Ph3 TALAPRO-2 trial in 399 pts w/ HRR-deficient mCRPC #prostatecancer 👉enza + tala vs. enza, rPFS HR 0.44, OS trending strongly HR 0.69, efficacy in multiple HRR gene subsets⬇️open access👉 @OncoAlert @PCF_Science

16

109

226

Last Seen Profiles

@heyliando

@PartaiSocmed

@lena_148

@ibakarachi

@lotnoklontong

@networkthoughts

@yulizaradexo

@bobbankvillage

@hagovluzutv

@kametoto

@NizerFN_

@bpthaber

@Tatogus

@diopmomoo

@dcastoART

@SydnieChristmas

@zedo_vv

@RecruiterJenni

@kirin_ojyou

@Wanted_Theories

@kayo41759763

@jaylianetteee_

@rinka6595581832

@senehata

@faidalll

@kaderuyulk

@Dbleki

@vividoloona_

@uncommonblin

@wamudraws

@NinjaJay1

@momo19nam

@Semasg1m

@jackkillah

@feminazliyim

@Mbbnnmmz

Neeraj Agarwal, MD, FASCO

@neerajaiims

5 years

The youngest person (38 yo) to achieve “Full Professor” in @cityofhope ’s history. Congrats to my dear friend @montypal ! 👏👏👏👏

104

40

594

Neeraj Agarwal, MD, FASCO

@neerajaiims

1 year

What a nice surprise in the mail from the @ASCO HQ this weekend👉 very honored to receive this “ Top Reviewer of 2022” award for the Journal of Clinical Oncology for the year 2022. @JCO_ASCO . Thanks to @DrJFriedberg #KathyMiller @BHaffty #michaelcarducci @emiliemgunn Ccing:

31

19

302

Neeraj Agarwal, MD, FASCO

@neerajaiims

2 years

Breaking news: Phase 3 randomized TALAPRO-2 trial of Enza + Talazoparib vs. Enza meets primary endpoint in the 1st line mCRPC #ProstateCancer in both HRR+ and HRR- patients (study design👇).Press release 👉 @OncoAlert @urotoday @Huntsman_GU @PCF_Science

15

138

287

Neeraj Agarwal, MD, FASCO

@neerajaiims

2 years

Breaking news: @US_FDA approves darolutamide (Nubeqa) for metastatic castration sensitive #prostatecancer in combination with docetaxel based on the results of ph3 Arasens trial👇 @PCF_Science @OncoAlert @urotoday

5

103

277

Neeraj Agarwal, MD, FASCO

@neerajaiims

4 years

Just in @NEJM 👉Feel very fortunate to be a part of this fantastic journey with PROfound-> 1st randomized trial to show improved OS in biomarker selected pts with mCRPC #prostatecancer OS even better after adjusting for 67% cross 👉 @Oncoalert @quimmateo

12

91

270

Neeraj Agarwal, MD, FASCO

@neerajaiims

3 years

Just in @NEJM :practice changing results in mRCC #kidneycancer 👉Remarkably improved OS, PFS, ORR with Cabozantinib + nivolumab versus sunitinib. QOL was also improved with the combo. Congrats to @DrChoueiri @motzermd @tompowles1 OncoAlert @urotoday 👇

6

93

254

Neeraj Agarwal, MD, FASCO

@neerajaiims

3 years

Before @montypal hit 30, his goal was to have 30 MEDLINE-cited papers. He then set his sights on >400 by 40 & elevated many trainees along the way. Congrats on hitting this personal milestone just ahead of your big day! @cityofhope @KidneyCancer @kidneycan

29

37

247

Neeraj Agarwal, MD, FASCO

@neerajaiims

3 years

Just in JCO @ASCO 👉Glad to share final OS data from TITAN trial after ~4 yrs of follow up: unprecedented OS benefit with APALUTAMIDE/ APA after adjusting for crossover from placebo👉48% reduction in risk of death with APA, HR=0.52 👇 @oncoalert @urotoday

8

105

244

Neeraj Agarwal, MD, FASCO

@neerajaiims

2 years

Press release👉Cosmic-313 ph 3 trial in 1st line mRCC #kidneycancer meets primary endpoint: ⬆️PFS with cabozantinib+nivolumab+ipilimumab vs. Nivolumab+ipilimumab (HR: 0.73; 95% CI: 0.57-0.94; P=0.01). OS immature. @DrChoueiri @AlbigesL @OncoAlert Weblink:

12

99

232

Neeraj Agarwal, MD, FASCO

@neerajaiims

3 years

Huge news for men with mCRPC #prostatecancer 👉Phase III VISION study with 177Lu-PSMA-617 meets primary endpoints of OS and rPFS in men with PSMA+ mCRPC “AFTER” prior Rx with Taxane & AR inhibitor. @OncoAlert @urotoday

7

94

238

Neeraj Agarwal, MD, FASCO

@neerajaiims

1 year

Breaking news👉 @FDAoncology approves the combo of abiraterone+Olaparib for mCRPC #prostatecancer with BRCA1 & BRCA2 mutations. Weblink: @ONCOALERT @PCFnews @urotoday @DrChoueiri @ZEROCancer @CancerDotNet #ASCO23 @ASCO

3

96

234

Neeraj Agarwal, MD, FASCO

@neerajaiims

1 year

Breaking news from #AUA23 @AmerUrological : @siadaneshmand presents 1st results from SunRISE-1 trial 👉TAR-200 (local gemcitabine delivery system in bladder) in BCG refractory high-risk non-muscle invasive #bladdercancer 👉 amazing ~73% complete response 👇 @OncoAlert @urotoday

8

81

231

Neeraj Agarwal, MD, FASCO

@neerajaiims

1 year

Breaking news👉 #ASCO2023 @ASCO Dr. #KarimFizazi presents the First results from all HRR positive 1st line mCRPC #ProstateCancer patients (n=399)from our phase 3 TALAPRO-2 trial👉Talazoparib + Enza significantly improves rPFS vs Enza (HR 0.45), OS trending well👇 @OncoAlert

4

81

231

Neeraj Agarwal, MD, FASCO

@neerajaiims

4 years

Visualizing “History of Pandemics” and where COVID-19 stands. Fantastic visual summary in this article by Nicholas LePan @VisualCap Weblink:

5

117

225

Neeraj Agarwal, MD, FASCO

@neerajaiims

2 years

Breaking news: Another huge setback to immunotherapy in mCRPC #prostatecancer 👉Ph3 trial of pembrolizumab + enzalutamide fails to improve survival outcomes. Trial design👇 @OncoAlert @PCF_Science @urotoday @guconnectinfo Weblink:

13

96

221

Neeraj Agarwal, MD, FASCO

@neerajaiims

2 years

Just in @TheLancet 👉Results of the Peace-1 trial: Triplet Rx with ADT+docetaxel+abiraterone ⬆️OS over ADT+docetaxel in high volume, denovo, mCSPC #prostatecancer . Abi can be considered in those starting ADT+docetaxel. Need biomarkers. @oncoalert Weblink:

4

95

221

Neeraj Agarwal, MD, FASCO

@neerajaiims

3 years

#GU21 @ASCO Very glad to present the unprecedented "Final OS" data from TITAN phase 3 trial of Apalutamide in new metastatic #ProstateCancer /mCSPC👇 Magnitude of OS even higher after adjusting for cross over (50%⬇️in risk of death)👇 @OncoAlert @urotoday

9

99

218

Neeraj Agarwal, MD, FASCO

@neerajaiims

3 years

Feel honored & privileged to be promoted to the Senior Director (aka Associate Director in many cancer centers) @huntsmancancer @UUtah comprehensive cancer center, reporting to our wonderful cancer center director @NeliMUlrich 👇Thanks to all @OncoAlert

Huntsman Cancer Institute

@huntsmancancer

3 years

We are pleased to announce Neeraj Agarwal ( @neerajaiims ) as senior director of clinical research innovation at HCI. #HCIproud

39

20

132

48

19

206

Neeraj Agarwal, MD, FASCO

@neerajaiims

4 years

Olaparib improves “Overall Survival” in men with BRCA 1/2 or ATM mutated metastatic CRPC in the updated analysis of the phase 3 Profound trial. First PARPi to show OS benefit in a randomized trial in #ProstateCancer

7

91

202

Neeraj Agarwal, MD, FASCO

@neerajaiims

2 years

Just in @JAMAOnc : Enzalutamide ⬇️ the risk of progression of low/intermediate risk #prostatecancer by 46% vs active surveillance/AS (HR:0.54)👉 may provide an alternative Rx option for pts undergoing AS 👉 @OncoAlert @urotoday #NealShore @dr_coops

32

80

195

Neeraj Agarwal, MD, FASCO

@neerajaiims

4 years

#ASCO20 Results from 3 large phase III registration trials (Prosper/Spartan/Aramis) in non-metastatic (M0)CRPC published on @ASCO meeting website today: Enza/ Apa/ Daro, all show OS benefit. Great news for our patients. @ASCO_pubs @ASCOPost Weblink:

2

90

192

Neeraj Agarwal, MD, FASCO

@neerajaiims

2 years

Breaking news👉 Ph3 PSMAfore trial with Pluvicto/ lutetium-177 met the primary endpoint of radiographic PFS in PSMA–positive mCRPC #prostatecancer after prior Rx with AR inhibitors but before chemotherapy👇Weblink👉 @OncoAlert @urotoday

0

86

183

Neeraj Agarwal, MD, FASCO

@neerajaiims

3 years

Just in @NEJM : Most breakthrough #COVID19 infections in fully vaccinated healthcare workers were mild, although 19% had persistent symptoms >6 weeks; 74% of patients had a high viral load at some point. Masking needs to continue for now. @OncoAlert

4

92

178

Neeraj Agarwal, MD, FASCO

@neerajaiims

2 years

Just in @TheLancetOncol Happy to report safety/efficacy of cabozantinib +atezolizumab in mCRPC #prostatecancer from Cosmic021 Ph1 study @montypal @DrChoueiri Promising results led to ongoing Ph3 Contact-2 trial 👇Weblink: @OncoAlert @PCF_Science @urotoday

11

60

180

Neeraj Agarwal, MD, FASCO

@neerajaiims

2 years

Just in @JCO_ASCO : Results of @theNCI funded Ph3 @SWOG 1216 in mCSPC # prostate cancer. Thanks to @SWOG leaders👇 for this opportunity. Design+ Results👇Great to see consistent ⬆️ in OS of our pts over time @OncoAlert @PrimoLaraMD @UUtah @huntsmancancer

18

59

175

Neeraj Agarwal, MD, FASCO

@neerajaiims

5 years

Feel very privileged & honored to join @JCO_ASCO EDITORIAL BOARD. Many thanks to @ASCO .Looking forward to work with esteemed GU oncology colleagues on the board: @MattGalsky @ERPlimackMD @apolo_andrea @NaomiHaas5 @CaPsurvivorship @lynnhenrymd @DrDarrenFeldman @ctangen1 @SWOG

37

14

171

Neeraj Agarwal, MD, FASCO

@neerajaiims

3 years

#GU21 @ASCO First randomized positive study in papillary metastatic RCC #kidneycancer i.e. @SWOG 1500's results are out: by @montypal @CityofHope_GU @PrimoLaraMD et al 👉"Cabozantinib" is new standard of care for these patients @OncoAlert @urotoday

ASCO

@ASCO

3 years

#GU21 abstracts are now available‼️ Preview the research ➡️

1

27

45

4

82

171

Neeraj Agarwal, MD, FASCO

@neerajaiims

3 years

#GU21 @ASCO King from @cityofhope is here with a bang👏👏 Establishes Cabozantinib as standard of care in metastatic papillary RCC #kidneycancer in this @SWOG1500 trial which just published in @TheLancet 👇 @oncoalert @PrimoLaraMD @urotoday @DrChoueiri @DrRaviSalgia @VivekSubbiah

5

69

166

Neeraj Agarwal, MD, FASCO

@neerajaiims

3 years

#GU21 @ASCO Practice changing data: Phase 3 trial of Enfortumab Vedotin (EV) vs SOC chemotherapy in 3rd line Rx of metastatic #bladder cancer by @tompowles1 @DrRosenbergMSK @sonpavde et al👉Significantly improved OS, PFS, ORR make EV as new SOC @OncoAlert

3

76

160

Neeraj Agarwal, MD, FASCO

@neerajaiims

2 years

Just in @TheLancetOncol 👉1st study (GALAHAD study) to show efficacy of niraparib in men with mCRPC #prostatecancer with DNA repair defects & prior Rx with NHTs & taxanes. ORR:34% in BRCA+, 10.6% non BRCA+. @OncoAlert @MAWJNJ @EfstathiouEleni @urotoday

0

64

157

Neeraj Agarwal, MD, FASCO

@neerajaiims

3 years

Just in @JAMAOnc : very thoughtful and a comprehensive review of systemic therapy in new metastatic #kidneycancer & how to navigate treatment selection by @DrDanielHeng @navstruck Must read👉

4

69

156

Neeraj Agarwal, MD, FASCO

@neerajaiims

2 years

Just in👉In mCRPC #ProstateCancer with ATM or BRCA2 mutations 👉improved outcomes when taxanes given first in ATM mutations, & vice versa with PARP inhibitors in BRCA2 mutations.👇Guidance for sequencing. Congrats @EAntonarakis Link: @OncoAlert @urotoday

2

63

152

Neeraj Agarwal, MD, FASCO

@neerajaiims

9 months

#ESMO23 @drlouiseemmett @ANZUPtrials presents: ENZA-P (ANSUP 1901) phase 2 trial results of Enza versus Enza + Lu-177 PSMA-617 in mCRPC #prostatecancer 👉Improved PSA PFS and rPFS with combo👇 @OncoAlert @urotoday @PCF_Science @APCCC_Lugano @myESMO

2

71

149

Neeraj Agarwal, MD, FASCO

@neerajaiims

4 years

Our study in @CCR_AACR today: 1st report from a federally funded prospective trial ( @SWOG S1216) in new metastatic #prostatecancer (mCSPC)👉showing tremendous negative impact of baseline CTCs on survival outcomes👇These men need novel trials @OncoAlert

6

60

149

Neeraj Agarwal, MD, FASCO

@neerajaiims

6 years

Low dose abiraterone 250 mg + prednisone 10 mg daily + low fat diet has non-inferior efficacy to abiraterone 1000 mg + 10 my prednisone daily in mCRPC: potential for huge cost saving @ASCO @JCO_ASCO @PCF_Science

6

123

146

Neeraj Agarwal, MD, FASCO

@neerajaiims

3 years

#ESMO21 @myESMO Very honored to present #LBA24 with my co-PI @montypal ,the exciting COSMIC-021 Ph 1 results in mCRPC #prostatecancer : compelling ORR/DCR + rPFS by RECEIST 1.1 in these men with aggressive PCa. Ph 3 CONTACT-2 trial ongoing @Huntsman_GU @OncoAlert @DrChoueiri

5

65

148

Neeraj Agarwal, MD, FASCO

@neerajaiims

2 years

#GU22 @ASCO Abs #13 👉Ph 3 ARASENS trial in pts with mHSPC #prostatecancer : Darolutamide+ADT + docetaxel significantly improved OS and key secondary endpoints vs ADT + docetaxel alone. @OncoAlert @PCF_Science @urotoday

0

65

146

Neeraj Agarwal, MD, FASCO

@neerajaiims

1 year

@Montypal never tires of highlighting and praising others’ work but rarely talks about his own accomplishments👉 THREE back-to-back FIRST author @TheLancet papers on original research in the last 3 yrs (2021, 2022, 2023). 👇👇👇Congrats Monty for being such a humble and generous

Sumanta K. Pal, MD, FASCO

@montypal

1 year

Mesmerized by all the elegant discussions today. First @neerajaiims , then @anis_a_hamid , then @BraunMDPhD & now @BourlonMaite ! Dr. Bourlon offers a clear and concise distillation of trials from @drenriquegrande , #DrSiefkerRadtke & @shilpaonc . So excited to have her mentee,

1

22

67

5

38

145

Neeraj Agarwal, MD, FASCO

@neerajaiims

4 years

#ASCO20 Plenary LBA1: “FANTASTIC” news in advanced #bladdercancer Ph 3 trial with “avelumab” front line maintenance Rx improves both OS & PFS.👇New SOC. Congrats @tompowles1 and very proud of dear friend @PGrivasMDPhD -> last author on a @ASCO plenary.👏

6

71

143

Neeraj Agarwal, MD, FASCO

@neerajaiims

3 years

Just heard the wonderful news 👉of our friend Dr Mehmet Asim Bilen’s @bilenma promotion to “Associate Professor” + “Director” of GU Medical Oncology at @WinshipAtEmory with in 5 yrs of finishing fellowship from @MDAndersonNews Congrats Asim!! Impressive record with >100 pubs👏👏

17

143

Neeraj Agarwal, MD, FASCO

@neerajaiims

3 years

Just in @TheLancet :Adding 2 yrs of abiraterone to ADT in men at high risk of relapse after radiation Rx to non-metastatic #ProstateCancer 👉improves MFS & OS (HR: 0.53 & 0.60). Practice changing data by @AttardLab @Prof_Nick_James et al @OncoAlert

1

63

139

Neeraj Agarwal, MD, FASCO

@neerajaiims

3 years

#ESMO21 Peace-1 trial results 👉Treatment of high volume denovo metastatic castration sensitive prostate cancer changes again👉triplet therapy with ADT+docetaxel+abiraterone is new standard of care option for fit patients. Congrats #KarimFizazi @GustaveRoussy @OncoAlert

3

61

137

Neeraj Agarwal, MD, FASCO

@neerajaiims

3 years

#ASCO21 @ASCO Plenary LBA1: Olympia Trial in @NEJM today👉In patients with high-risk, HER2-localized breast cancer & germline BRCA1/BRCA2 mutations, adjuvant Rx with olaparib significantly improves survival free of invasive or distant disease than placebo. @oncolaert @Andrewtutt

1

52

136

Neeraj Agarwal, MD, FASCO

@neerajaiims

4 years

#Bladdercancer therapeutics beyond PD-1/-L1 inhibitors : Comprehensive description of novel targets/ drugs and breathtaking list of novel clinical trials. Must read #ASCO21 @ASCO education book article: @ASCO_pubs by @PGrivasMDPhD @sonpavde

6

63

134

Neeraj Agarwal, MD, FASCO

@neerajaiims

9 months

#ESMO23 Presidential session talk by #OliverSartor 👉 177Lu-PSMA-617 shows superiority to ARPI change in taxane-naïve pts w/ mCRPC #prostatecancer : Lutetium vs ARPI change 👉57% reduction in risk of progression 👇 @OncoAlert @urotoday @Uromigos @APCC

3

68

133

Neeraj Agarwal, MD, FASCO

@neerajaiims

4 years

Very interesting paper in @JCOPO_ASCO : denovo metastatic #prostatecancer has similar genomic profile to that in heavily pretreated mCRPC (except no AR aberrations and low RB loss). Great team work by Stampede investigators @scserendipity1 @MaxParmarMRCUCL

2

64

131

Neeraj Agarwal, MD, FASCO

@neerajaiims

3 years

Just in @JCO_ASCO 👉 Bipolar androgen Rx/BAT was as efficacious as enzalutamide after abiraterone in mCRPC #ProstateCancer . Fantastic collaboration including @huntsmancancer Great outcome with enza after BAT 👇 @EAntonarakis @sonpavde @OncoAlert @urotoday

3

54

128

Neeraj Agarwal, MD, FASCO

@neerajaiims

1 year

#GU23 @ASCO Much awaited data from the ph3 Propel shows continued rPFS benefits + strong trend for OS (7 month) benefit with abiraterone + olaparib vs. abiraterone in 1st line mCRPC in HRR pos & neg #prostatecancer 👇 @OncoAlert @PCF_Science @MedIQCME #MedIQGU23

5

61

126

Neeraj Agarwal, MD, FASCO

@neerajaiims

1 year

📢 Breaking News: @ASCO 2023 annual meeting abstracts are now available ‼️ Access them here👉 #ASCO23 @OncoAlert @urotoday @PCFnews @SWOG @Uromigos @OncBrothers @montypal @DrChoueiri @PGrivasMDPhD @shilpaonc @apolo_andrea

2

47

127

Neeraj Agarwal, MD, FASCO

@neerajaiims

3 years

Just in: Propel trial of PARP inhibitor Olaparib + abiraterone in UNSELECTED pts in 1st line mCRPC #ProstateCancer meets its primary end point:rPFS Results bode well for ongoing trials with Enza+ Talazoparib and Abi+ Niraparib👇 @OncoAlert @urotoday

7

54

124

Neeraj Agarwal, MD, FASCO

@neerajaiims

3 years

Just in @JACCJournals :How to treat men with #prostatecancer with ADT and minimize cardiovascular side effect! Excellent article (must read) by #viveknarayab @CaPsurvivorship Alicia Morgans @DanaFarber_GU #survivorship Open access👉 @OncoAlert @PCF_Science

1

68

124

Neeraj Agarwal, MD, FASCO

@neerajaiims

4 years

Rucaparib ( PARPi) FDA approved today for mCRPC #ProstateCancer with germline/somatic BRCA1/BRCA2 mutations, with prior novel AR directed Rx AND a taxane chemoRx. Tumor genomic sequencing is standard of care now. Kudos to @charlesryanmd & Triton 2 team.

4

49

119

Neeraj Agarwal, MD, FASCO

@neerajaiims

3 years

Startling figures in metastatic #bladdercancer here 👉>50% pts never receive any Rx & only 17% receive 2nd line Rx. Suggesting solutions here👇alongside the most brilliant minds in the field @umangtalking @montypal @PGrivasMDPhD Open access article👉

15

49

121

Neeraj Agarwal, MD, FASCO

@neerajaiims

1 year

Just in @pcan_journal 👉mHSPC #prostatecancer pts not achieving a PSA ≤ 0.2 ng/ml on intensified ADT had ⬇️PFS & OS (median OS ~39 months). Weblink👉 Congrats @ggebraelmd @nsayeghmd @vinay_onc @umangtalking @Huntsman_GU @OncoAlert @urotoday @PCF_Science

9

52

123

Neeraj Agarwal, MD, FASCO

@neerajaiims

5 years

Titan update today in #ESMO19 & in @TheLancetOncol in men with mCSPC, Apalutamide+ADT significantly improves OS and rPFS while maintaining HRQOL despite deeper AR blockade. Remarkably NO increase in Fatigue. @ASCO @NeliMUlrich @huntsmancancer @montypal

1

62

119

Neeraj Agarwal, MD, FASCO

@neerajaiims

1 year

#ASCO23 @ASCO @DrChoueiri present the data on Contact-3 trial which addresses a major question in the #mRCC #kidneycancer field 👉Is there a role of ICI Re-challenge? Answer is “NO”. This study does change my practice in many patients. Congrats for the simultaneous @theLancet

1

47

120

Neeraj Agarwal, MD, FASCO

@neerajaiims

2 years

Just in @JAMANetworkOpen In this multicenter study of 741 pts with mCRPC #prostatecancer , TMB ≥ 10 mt/Mb had significantly ⬆️ time to next Rx ( TTNT) & OS with ICIs vs taxanes. Open access👉 @OncoAlert @urotoday @RyonGraf @nsayeghmd Thanks @navstruck !!

Vishal Navani, MD

@navstruck

2 years

Congratulations @neerajaiims & @Roche outlining the importance of sequencing patients with mcrpc. Using a more practical endpoint TTNT they outline the potential for #immunotherapy even in the immune desert of #prostatecancer in a study nested in RWE #oncology @JAMANetworkOpen

0

3

11

9

54

120

Neeraj Agarwal, MD, FASCO

@neerajaiims

4 years

#ESMO20 @myESMO Cabozantinib on the roll!! @montypal presents the results of our Cosmic021 Trial in MRCC #kidneycancer (results similar to 9ER)👉🏻rPFS: 19.5 mos, ORR: 53%, Disease control rate: 94%. Based on these data, Ph 3 Contact-3 trial in salvage Rx mRCC started👇 @OncoAlert

2

49

116